Eli Lilly commits $5.3B to more Zepbound, Mounjaro production
![Eli Lilly commits 53B to more Zepbound Mounjaro production](/thumb/phpThumb.php?src=%2Fuploads%2Fnews%2F47%2F4797%2F8%2F4797802-eli-lilly-commits-53b-to-more-zepbound-mounjaro-production.jpg&w=706&hash=4070961adea29a310e8dfd344daeb884)
Two Eli Lilly manufacturing plants in Indiana are getting a $5.3 billion boost to increase production of Zepbound and Mounjaro, the company said May 24.
The investment "represents the single largest investment in synthetic medicine [active pharmaceutical ingredient] manufacturing in U.S. history," Eli Lilly's chair and CEO David Ricks said in a news release.
Leaders of the manufacturing sites in Lebanon, Ind., will hire 200 full-time workers to help increase production. Mounjaro is approved for Type 2 diabetes and Zepbound is indicated for chronic weight management. Eli Lilly is also eyeing a Zepbound label expansion after finding positive results in a sleep apnea trial.
The announcement raises the company's total investment in the Lebanon site from $3.7 billion to $9 billion.